李 洁,张 媛,张俊勤,田 菲,韩 华.经皮神经电刺激联合布洛芬缓释胶囊对盆腔炎性疾病所致慢性盆腔疼痛患者血清炎症因子和致痛物质水平的影响[J].现代生物医学进展英文版,2023,(1):197-200. |
经皮神经电刺激联合布洛芬缓释胶囊对盆腔炎性疾病所致慢性盆腔疼痛患者血清炎症因子和致痛物质水平的影响 |
Effect of Transcutaneous Electrical Nerve Stimulation Combined with Ibuprofen Sustained-Release Capsule on Serum Inflammatory Factors and Pain Causing Substances in Patients with Chronic Pelvic Pain Caused by Pelvic Inflammatory Disease |
Received:May 07, 2022 Revised:June 03, 2022 |
DOI:10.13241/j.cnki.pmb.2023.01.039 |
中文关键词: 经皮神经电刺激 布洛芬缓释胶囊 盆腔炎性疾病 慢性盆腔疼痛 疗效 炎症因子 致痛物质 |
英文关键词: Transcutaneous electrical nerve stimulation Ibuprofen sustained-release capsules Pelvic inflammatory disease Chronic pelvic pain Efficacy Inflammatory factors Pain-causing substances |
基金项目:河北省医学科学研究重点课题计划项目(20170282) |
|
Hits: 506 |
Download times: 381 |
中文摘要: |
摘要 目的:观察经皮神经电刺激(TENS)联合布洛芬缓释胶囊治疗盆腔炎性疾病(PID)所致慢性盆腔疼痛(CPP)的疗效及对血清炎症因子和致痛物质水平的影响。方法:选择2020年6月~2021年6月期间河北省人民医院收治的120例PID所致CPP患者。根据随机数字表法分为对照组和研究组,各为60例,对照组患者接受布洛芬缓释胶囊治疗,研究组患者接受TENS联合布洛芬缓释胶囊治疗,对比两组疗效、症状评分、血清炎症因子、致痛物质水平和安全性情况。结果:研究组(91.67%)的临床总有效率高于对照组(75.00%),差异有统计学意义(P<0.05)。治疗后,两组疼痛视觉模拟(VAS)评分、症状体征(McCormack)评分均下降,研究组低于对照组同期(P<0.05)。治疗后,两组血清肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)、白介素-1β(IL-1β)、C反应蛋白(CRP)水平均下降,研究组低于对照组同期(P<0.05)。治疗后,两组血清5-羟色胺(5-HT)、P物质(SP)和强啡肽(DYN)水平均下降,研究组低于对照组同期(P<0.05)。两组不良反应发生率组间对比,未见差异(P>0.05)。结论:TENS联合布洛芬缓释胶囊治疗PID所致CPP,疗效确切,可促进症状缓解,降低炎症因子和致痛物质水平。 |
英文摘要: |
ABSTRACT Objective: To observe the efficacy of transcutaneous electrical nerve stimulation (TENS) combined with ibuprofen sustained-release capsules in the treatment of chronic pelvic pain (CPP) caused by pelvic inflammatory disease (PID) and the effects on the levels of serum inflammatory factors and pain-causing substances. Methods: 120 patients with CPP who were caused by PID admitted to Hebei Provincial People's Hospital from June 2020 to June 2021 were selected. They were divided into control group and study group according to random number table method, 60 cases in each group. The patients in the control group were treated with ibuprofen sustained-release capsules, while the patients in the study group were treated with TENS combined with ibuprofen sustained-release capsules, the efficacy, symptom score, serum inflammatory factors and pain-causing substances levels and safety between the two groups were compared between the two groups. Results: The total clinical effective rate of the study group (91.67%) was higher than that of the control group (75%), and the difference was statistically significant(P<0.05). After treatment, visual analogue scale (VAS) score and symptom and sign (McCormack) score of pain decreased in the two groups, the study group was lower than the control group in the same period (P<0.05). After treatment, serum levels of tumor necrosis factor -α(TNF-α), interleukin-6 (IL-6), interleukin-1β(IL-1β) and C-reactive protein(CRP) decreased in the two groups, the study group was lower than that of the control group in the same period (P<0.05). After treatment, serum levels of 5-hydroxytryptophan (5-HT), substance P (SP) and strong enkephalin (DYN) decreased in the two groups, the study group was lower than that of the control group in the same period (P<0.05). There was no difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: TENS combined with ibuprofen sustained-release capsules in the treatment of CPP caused by PID, efficacy is definite, can promote symptom relief, reduce inflammatory factors and pain-causing substances level. |
View Full Text
View/Add Comment Download reader |
Close |